About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Sub-IndustryHealth Care Equipment
SymbolNYSEAMERICAN:NAVBPrevious Symbol: NYSEMKT:NAVB
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-65.90%
Return on Assets-42.98%
Frequently Asked Questions for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
What is Navidea Biopharmaceuticals' stock symbol?
Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."
How were Navidea Biopharmaceuticals' earnings last quarter?
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company earned $0.22 million during the quarter. Navidea Biopharmaceuticals had a negative return on equity of 65.90% and a negative net margin of 515.33%. View Navidea Biopharmaceuticals' Earnings History.
Are investors shorting Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals saw a decrease in short interest in October. As of October 31st, there was short interest totalling 4,493,794 shares, a decrease of 2.8% from the October 13th total of 4,621,391 shares. Based on an average daily volume of 901,427 shares, the days-to-cover ratio is presently 5.0 days. Approximately 2.9% of the shares of the company are sold short.
Who are some of Navidea Biopharmaceuticals' key competitors?
Some companies that are related to Navidea Biopharmaceuticals include Compugen (CGEN), Asterias Biotherapeutics (AST), Advaxis (ADXS), Oramed Pharmaceuticals (ORMP), CTI BioPharma Corp. (CTIC), ArQule (ARQL), aTyr Pharma (LIFE), Eiger BioPharmaceuticals (EIGR), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), Infinity Pharmaceuticals (INFI), Sunesis Pharmaceuticals (SNSS), Galectin Therapeutics (GALT), Regulus Therapeutics (RGLS), Senomyx (SNMX), Novelion Therapeutics (NVLN), Brainstorm Cell Therapeutics (BCLI) and NovaBay Pharmaceuticals (NBY).
Who are Navidea Biopharmaceuticals' key executives?
Navidea Biopharmaceuticals' management team includes the folowing people:
- Eric K. Rowinsky M.D., Chairman of the Board (Age 60)
- Michael M. Goldberg M.D., President, Chief Executive Officer, Director (Age 57)
- Jed A Latkin, Chief Financial Officer, Interim Chief Operating Officer, Chief Accounting Officer (Age 41)
- Frederick O. Cope Ph.D., Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer (Age 69)
- William J. Regan, Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer (Age 63)
- Mark I. Greene M.D. Ph.D., Director (Age 67)
- Michael Rice, Director (Age 51)
Who owns Navidea Biopharmaceuticals stock?
Navidea Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Sowell Financial Services LLC (0.42%). Company insiders that own Navidea Biopharmaceuticals stock include Brent L Larson, Jed Latkin and William J Regan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.
Who sold Navidea Biopharmaceuticals stock? Who is selling Navidea Biopharmaceuticals stock?
How do I buy Navidea Biopharmaceuticals stock?
Shares of Navidea Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Navidea Biopharmaceuticals' stock price today?
One share of Navidea Biopharmaceuticals stock can currently be purchased for approximately $0.41.
How big of a company is Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals has a market capitalization of $67.52 million.
How can I contact Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.
MarketBeat Community Rating for Navidea Biopharmaceuticals (NAVB)MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Analysts' Ratings History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History and Estimates Chart for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Earnings History by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||($0.01)||$0.22 million||View||N/A|
|8/8/2017||Q2 2017||($0.02)||$0.61 million||View||Listen|
|3/29/2017||Q4 2016||($0.02)||$3.36 million||View||N/A|
|8/4/2016||Q216||($0.03)||($0.04)||$5.24 million||$5.40 million||View||N/A|
|5/17/2016||Q1||($0.03)||($0.02)||$4.63 million||$4.70 million||View||Listen|
|3/23/2016||Q415||($0.04)||($0.02)||$3.70 million||$4.00 million||View||Listen|
|11/4/2015||Q315||($0.04)||($0.05)||$2.40 million||$3.98 million||View||Listen|
|7/30/2015||Q215||($0.04)||($0.06)||$2.18 million||$2.90 million||View||Listen|
|5/12/2015||Q115||($0.03)||($0.05)||$3.30 million||$2.10 million||View||Listen|
|3/5/2015||($0.04)||($0.05)||$1.95 million||$2.20 million||View||N/A|
|3/5/2015||($0.04)||($0.05)||$1.95 million||$2.20 million||View||N/A|
|3/5/2015||Q414||($0.05)||($0.05)||$2.10 million||$2.20 million||View||Listen|
|11/6/2014||Q314||($0.06)||($0.05)||$1.54 million||$2.30 million||View||Listen|
|8/6/2014||Q214||($0.07)||($0.07)||$1.05 million||$1.05 million||View||Listen|
|5/7/2014||Q114||($0.10)||($0.06)||$0.90 million||$0.75 million||View||Listen|
|3/6/2014||Q413||($0.08)||($0.10)||$0.74 million||$0.54 million||View||Listen|
|11/6/2013||Q313||($0.08)||$0.09||$0.97 million||$0.40 million||View||Listen|
|8/7/2013||Q2 2013||($0.07)||($0.09)||$0.55 million||$0.20 million||View||N/A|
|5/8/2013||Q1 2013||($0.07)||($0.06)||$0.02 million||View||N/A|
Earnings Estimates for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)
Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/29/2017||William J Regan||SVP||Buy||20,000||$0.53||$10,600.00|| |
|5/30/2017||Jed Latkin||CFO||Buy||7,600||$0.44||$3,344.00|| |
|5/22/2017||Jed Latkin||CFO||Buy||25,359||$0.45||$11,411.55|| |
|12/1/2015||Brent L Larson||CFO||Sell||12,500||$1.50||$18,750.00|| |
|10/1/2015||Brent L Larson||CFO||Sell||12,500||$2.27||$28,375.00|| |
|9/1/2015||Brent L Larson||CFO||Sell||12,500||$1.88||$23,500.00|| |
|6/1/2015||Brent L Larson||CFO||Sell||12,500||$1.24||$15,500.00|| |
|5/29/2015||Gordon A Troup||Director||Buy||10,000||$1.31||$13,100.00|| |
|11/14/2014||Michael M Goldberg||Director||Buy||100,000||$1.08||$108,000.00|| |
|11/10/2014||Brendan A Ford||Director||Buy||10,000||$1.03||$10,300.00|| |
|5/9/2014||Mark Jerome Pykett||CEO||Buy||10,000||$1.34||$13,400.00|| |
|3/10/2014||Brent Larson||CFO||Sell||41,500||$1.96||$81,340.00|| |
|3/10/2014||Frederick Cope||SVP||Sell||15,000||$1.96||$29,400.00|| |
|3/10/2014||Mark Jerome Pykett||CEO||Sell||120,000||$1.96||$235,200.00|| |
|11/8/2013||Brendan Ford||Director||Buy||20,000||$1.45||$29,000.00|| |
|11/8/2013||Brent Larson||CFO||Buy||5,000||$1.39||$6,950.00|| |
|11/8/2013||Frederick Cope||SVP||Buy||3,500||$1.43||$5,005.00|| |
|11/8/2013||Mark Jerome Pykett||CEO||Buy||10,900||$1.35||$14,715.00|| |
|3/15/2013||Gordon A Troup||Director||Buy||7,000||$2.70||$18,900.00|| |
|3/15/2013||Mark Jerome Pykett||CEO||Buy||1,850||$2.70||$4,995.00|| |
|3/15/2013||Thomas H Tulip||EVP||Buy||17,500||$2.82||$49,350.00|| |
|3/15/2013||William J Regan||SVP||Buy||5,000||$2.71||$13,550.00|| |
|9/14/2012||Thomas H Tulip||EVP||Buy||15,000||$2.70||$40,500.00|| |
|9/12/2012||Brendan A Ford||Director||Buy||5,000||$2.64||$13,200.00|| |
|9/11/2012||Mark Jerome Pykett||CEO||Buy||4,000||$2.64||$10,560.00|| |
Latest Headlines for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Chart for Friday, November, 24, 2017